Universal Biosensors Inc logo

UBI - Universal Biosensors Inc Share Price

A$0.2 0.0  5.3%

Last Trade - 5:42am

Sector
Healthcare
Size
Micro Cap
Market Cap £18.6m
Enterprise Value £-9.25m
Revenue £33.0m
Position in Universe 1010th / 1855
Bullish
Bearish
Unlock UBI Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

UBI Revenue Unlock UBI Revenue

Net Income

UBI Net Income Unlock UBI Revenue

Normalised EPS

UBI Normalised EPS Unlock UBI Revenue

PE Ratio Range

UBI PE Ratio Range Unlock UBI Revenue

Dividend Yield Range

UBI Dividend Yield Range Unlock UBI Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2019
31st Dec 2020
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
UBI EPS Forecasts Unlock UBI Revenue
Profile Summary

Universal Biosensors, Inc. is a specialist medical diagnostics company. The Company is focused on the research, development and manufacture of in vitro diagnostic test devices for consumer and professional point-of-care use. The Company's subsidiary, Universal Biosensors Pty Ltd, conducts its research, development and manufacturing activities. The Company uses its electrochemical cell technology platform to develop point-of-care testing systems for a range of different markets. The Company is engaged in the development of its own Prothrombin Time International Normalized Ratio (PT-INR) test for use in decentralized settings, including the patient self-test market. It is engaged in demonstrating the various applications of its technology platform, including its application to diagnostic tests based on enzymatic, immunoassay and molecular diagnostic methods. It has developed a blood glucose test with LifeScan, Inc. and a coagulation PT-INR test with Siemens Healthcare Diagnostics Inc.

Directors
Last Annual December 31st, 2018
Last Interim June 30th, 2019
Incorporated September 14, 2001
Public Since December 13, 2006
No. of Shareholders: n/a
No. of Employees: 97
Sector Healthcare
Industry Healthcare Equipment & Supplies
Index
Exchange Australian Stock Exchange - SEATS
Shares in Issue 177,546,854
Free Float (0.0%)
Eligible for
ISAs
SIPPs
UBI Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for UBI
Upcoming Events for UBI
Similar to UBI
© Stockopedia 2019, Thomson Reuters, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.